CMPS - Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective AMA Study Finds | Benzinga
A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provided preliminary data on the treatment’s safety and efficacy, reported Marijuana Moment’s Ben Adlin.
Published by the Journal of the American Medical Association (JAMA Psychiatry,) the small pilot study’s findings suggest Safe of one 25mg dose of the biotech’s synthetic psilocybin COMP360 paired with psychotherapy for treating the mentioned mental health condition, a "treatment-resistant cyclical mood disorder” commonly associated with debilitating and difficult-to-treat depressive episodes.
See Also: COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression
The study, conducted at Baltimore’s Sheppard Pratt Hospital, was non-randomized and placebo-controlled and involved 15 participants with "well-documented” treatment-resistant BDII depression of marked severity and a lengthy duration of the current depressive episode.
Its design involved seven psychotherapy sessions: three pre-treatment (aka preparation,) one during psilocybin dosing (eight hours) and three post-treatment (aka integration.)
Study PI, Dr. Scott Aaronson said the results are encouraging and further support the clinical study of psychedelics in patients with treatment-resistant bipolar II.
"One participant compared ...